Drugs / RE001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06545201 | Aug 2024 → Apr 2026 overdue | — | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RE001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06545201 ↗ |
| Modality | Cell therapy | “T cell receptor engineered T cell therapy (TCR-T) treatment” NCT06545201 ↗ |